A phase I/II clinical trial of Ad-SGE-REIC for malignant pleural mesothelioma

Kyorin Pharmaceutical Co.,LTD0 个研究点目标入组 18 人开始时间: 2015年8月24日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Histologic diagnosis of malignant pleural mesothelioma
•-Patients must have measurable lesions, which are diagnosed.
•-Patients refractory to the chemotherapy including pemetrexed or Patients who cannot undergo chemotherapy, Patients who refuse the systemic chemotherapy for malignant pleural mesothelioma.
•-ECOG Performance status score: 0 - 2
•-Prior radiotherapy must be completed at least 4 weeks before study enrollment, and the patients must have recovered from the toxic effects of the treatment prior to case entry.
•-If chemotherapy was performed before study enrollment, prior chemotherapy must be completed at least 4 weeks and the patients must have recovered from the toxic effects of the treatment prior to case entry.
•-Patients who have adequate main organs function
•- Patients expected to be alive for at least 12 weeks before study enrollment

•-Patients with recurrent malignant pleural mesothelioma after surgical therapy or Patients with pneumonectomy due to the disease other than malignant pleural mesothelioma
•-Patients with simultaneous tumor and/or metachronaus tumor (excluding patients with them whose disease-free interval is over 2 years)
•-Patients with brain metastasis
•-Patients who have received prior any gene therapies and immunotherapies

发起方